Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Sanofi’s Sarclisa combined with Velcade ...

Sanofi gets rated buy today ... as it has been driving revenue from multiple products rather than a single magic drug.

Delve into Sanofi's "play to win" strategy as investments are ramping up after their consumer health division's divestment.

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

Products that do not qualify for NAS status are considered to fall under the existing period of exclusivity of the previously authorised product, and for alglucosidase alfa. Sanofi said it would ...

French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland ...

Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare ...

Paris: Sanofi has announced that the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) ...

Sanofi entered into exclusive talks to sell ... We sell different types of products and services to both investment professionals and individual investors. These products and services are usually ...

The partnership also allows Sanofi to use the company's adjuvant, Matrix-M, which helps boost the effectiveness of the ...

Sanofi India net profit down 46% in quarter ended September 30: Our Bureau, New Delhi Friday, November 8, 2024, 11:35 Hrs [IST] Sanofi India has registered 46 per cent decline in ...